Myeloma Trial, Recruiting
Who may be able to join
AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI
Who might be able to join this trial:
- You have recently been diagnosed with multiple myeloma (a type of blood cancer) for the first time
- You are planning to receive your first round of treatment for this condition at the research center running the trial
- Your planned treatment includes at least one of a specific group of medicines used for multiple myeloma — such as proteasome inhibitors, immunomodulatory drugs, or anti-CD38 antibodies — either on their own or combined with other treatments (confirm with trial site if unsure which category your treatment falls into)
- You are 18 years old or older
- You are able to understand what the study involves and what the follow-up process requires
- You are willing to sign and date a written consent form agreeing to take part
Who may not be able to join:
- You did not receive any follow-up care or appointments after your initial diagnosis
Important: Always verify eligibility with the trial site directly before applying.
Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.
Contact this trial
Principal Investigator: Prof. LU, MD, Peking University People's Hospital
Phone: +8613716926210
Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.
GP referral letter
Print a one-page summary to share with your doctor.
Trial details
Where this trial is recruiting
Primary endpoints
treatment patterns; real-world overall response rate (rwORR)
Can't join this trial?
Data last synced from ClinicalTrials.gov: 28 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.